Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naloxegol effect on GI transit in healthy subjects
NCT02737059Phase 1Completed
- Start
- Jul 2016
- Primary completion
- May 2017
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of naloxegol in opioid-induced constipation (OIC) (4 arms). Primary endpoints: Gastric emptying half-time at Day 2, Colonic filling percentage at 6 hours and 1 more. Started Jul 2016; status: completed.
02
Drugs
naloxegol
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT02737059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02737059.